Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Treasury Shares (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Treasury Shares for 8 consecutive years, with $966.6 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 38.84% to $966.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $966.6 million through Dec 2025, up 38.84% year-over-year, with the annual reading at $966.6 million for FY2025, 38.84% up from the prior year.
  • Treasury Shares hit $36.6 million in Q4 2025 for Corcept Therapeutics, up from $36.0 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $36.6 million in Q4 2025 to a low of $20000.0 in Q1 2024.
  • Historically, Treasury Shares has averaged $9.3 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest five-year swings in Treasury Shares: surged 441.48% in 2021 and later rose 5.97% in 2024.
  • Year by year, Treasury Shares stood at $410.4 million in 2021, then increased by 11.14% to $456.1 million in 2022, then skyrocketed by 39.23% to $635.1 million in 2023, then increased by 9.62% to $696.2 million in 2024, then soared by 38.84% to $966.6 million in 2025.
  • Business Quant data shows Treasury Shares for CORT at $966.6 million in Q4 2025, $923.3 million in Q3 2025, and $866.9 million in Q2 2025.